Companies

ImmunoGen

NASDAQ: IMGN
$31.23
▲ $0.00 (+0.00%) today
Markets open · 1:59pm ET

IMGN Coverage

12:04pm ET
Health and Healthcare

ImmunoGen Sees Solid Win With FDA Update

ImmunoGen shares pushed higher to start out the week when the FDA provided an update for the firm’s treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

Chris Lange
10:15am ET
Health and Healthcare

Ovarian Cancer Study Suffers Big Setback

ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.

Chris Lange